Drug metabolism and hypersensitivity reactions to drugs

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 4, 2015, Pages 277-284

  Agúndez, José A G ^a   Mayorga, Cristobalina ^b   García Martin, Elena ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

amoxicillin; aspirin; biotransformation; diclofenac; haptenization; hypersensibility; metabolism

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BIOLOGICAL MARKER; DICLOFENAC; DIPYRONE; DRUG METABOLIZING ENZYME; LEFLUNOMIDE; PARACETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMA PROTEIN;

DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSFORMATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; METABOLITE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETICS; MASS SPECTROMETRY; METABOLISM; PHARMACOGENETICS;

AMOXICILLIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PROTEINS; DRUG HYPERSENSITIVITY; HUMANS; MASS SPECTROMETRY; PHARMACOGENETICS;

EID: 84937780807     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000174     Document Type: Review

References (73)

1. Dona I, Barrionuevo E, Blanca-Lopez N, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014; 24: 143-153; quiz 1 p following 53
2. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-316
3. Wedi B. Definitions and mechanisms of drug hypersensitivity. Expert Rev Clin Pharmacol 2010; 3: 539-551
4. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15: 209-217
5. Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillinallergic individuals. J Immunol 1995; 155: 2670-2678
6. Pichler WJ, Beeler A, Keller M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006; 55: 17-25
7. Ariza A, Montanez MI, Perez-Sala D. Proteomics in immunological reactions to drugs. Curr Opin Allergy Clin Immunol 2011; 11: 305-312
8. Pirmohamed M, Aithal GP, Behr E, et al. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011; 89: 784-785
9. Fernandez TD, Mayorga C, Torres MJ, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 2008; 63: 712-719
10. Mayorga C, Torres MJ, Fernandez J, et al. Cutaneous symptoms in drug allergy: what have we learnt? Curr Opin Allergy Clin Immunol 2009; 9: 431-436
11. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-1077
12. Agundez JA, Lucena MI, Martinez C, et al. Assessment of nonsteroidal antiinflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011; 7: 817-828
13. Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8-And CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009; 5: 607-620
14. Agundez JA. Recent advances in drug intolerance. Curr Drug Metab 2009; 10: 946
15. Andreu I, Mayorga C, Miranda MA. Metabolomics in drug intolerance. Curr Drug Metab 2009; 10: 947-955
16. Zhang L, Hu J, Zhu R, et al. Degradation of paracetamol by pure bacterial cultures and their microbial consortium. Appl Microbiol Biotechnol 2013; 97: 3687-3698
17. Kaddurah-Daouk R, Weinshilboum RM; Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 2014; 95: 154-167
18. Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci U S A 2009; 106: 14187-14188
19. Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106: 14728-14733
20. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab 2009; 10: 236-246
21. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am 2010; 94: 805-820; xii
22. Aung AK, Haas DW, Hulgan T, Phillips EJ. Pharmacogenomics of antimicrobial agents. Pharmacogenomics 2014; 15: 1903-1930
23. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347
24. Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PloS One 2013; 8: e68111
25. Gueant JL, Romano A, Cornejo-Garcia JA, et al. HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. J Allergy Clin Immunol 2015; 135: 253-259
26. Garzon D, Ariza A, Regazzoni L, et al. Mass spectrometric strategies for the identification and characterization of human serum albumin covalently adducted by amoxicillin: ex vivo studies. Chem Res Toxicol 2014; 27: 1566-1574
27. Ariza A, Collado D, Vida Y, et al. Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic. PloS One 2014; 9: e90891
28. Hermo MP, Gomez-Rodriguez P, Barbosa J, Barron D. Metabolomic assays of amoxicillin, cephapirin and ceftiofur in chicken muscle: application to treated chicken samples by liquid chromatography quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 2013; 85: 169-178
29. Szultka M, Krzeminski R, Jackowski M, Buszewski B. Identification of in vitro metabolites of amoxicillin in human liver microsomes by LC-ESI/MS. Chromatographia 2014; 77: 1027-1035
30. Junza A, Montane A, Barbosa J, et al. High resolution mass spectrometry in the identification of transformation products and metabolites from beta-lactam antibiotics in thermally treated milk. J Chromatogr A 2014; 1368: 89-99
31. Blanca M, Garcia J, Vega JM, et al. Anaphylaxis to penicillins after nontherapeutic exposure: an immunological investigation. Clin Exp Allergy 1996; 26: 335-340
32. Torres MJ, Ariza A, Fernandez J, et al. Role of minor determinants of amoxicillin in the diagnosis of immediate allergic reactions to amoxicillin. Allergy 2010; 65: 590-596
33. Franski R, Czerniel J, Kowalska M, FranskaM. Electrospray ionization collisioninduced dissociation tandem mass spectrometry of amoxicillin and ampicillin and their degradation products. Rapid Commun Mass Spectrom 2014; 28: 713-722
34. Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol 2009; 9: 293-297
35. Blanca M, Perez E, Garcia JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989; 62: 295-298
36. Agundez JA, Martinez C, Perez-Sala D, et al. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10: 998-1008
37. Palikhe NS, Kim SH, Nam YH, et al. Polymorphisms of aspirin-metabolizing enzymes CYP2C9, NAT2 and UGT1A6 in aspirin-intolerant urticaria. Allergy Asthma Immunol Res 2011; 3: 273-276
38. Hammond TG, Meng X, Jenkins RE, et al. Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients. J Pharmacol Exp Ther 2014; 350: 387-402
39. Stachulski AV. Chemistry and reactivity of acyl glucuronides. Curr Drug Metab 2011; 12: 215-221
40. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281
41. Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004; 141: 205-208
42. Blanco G, Martinez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008; 18: 37-43
43. Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009; 10: 781-834
44. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-518
45. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003; 4: 319-329
46. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal antiinflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33: 1027-1035
47. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006; 10: 29-40
48. Harrer A, Lang R, Grims R, et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PloS One 2010; 5: e13707
49. Gomez E, Blanca-Lopez N, Torres MJ, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009; 39: 1217-1224
50. Martinez C, Andreu I, Amo G, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol 2014; 92: 457-466
51. Damm D. Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography. Arzneimittelforschung 1989; 39: 1415-1417
52. Zylber-Katz E, Granit L, Levy M. Formation and excretion of dipyrone metabolites in man. Eur J Clin Pharmacol 1992; 42: 187-191
53. Levy M, Flusser D, Zylber-Katz E, Granit L. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 1984; 27: 453-458
54. Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995; 25: 417-427
55. Ariza A, Torres MJ, Garcia-Martin E, et al. Basophil activation test with dipyrone metabolites in the evaluation of immediate allergic reactions to dipyrone. Allergy 2014; 69: 133
56. Kang SH, Jung YH, Kim HY, et al. Effect of paracetamol use on the modification of the development of asthma by reactive oxygen species genes. Ann Allergy Asthma Immunol 2013; 110: 364-369; e1
57. Kim JM, Park BL, Park SM, et al. Association analysis of N-Acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics 2010; 11: 951-958
58. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29: 400-411
59. Andrade RJ, Agundez JA, Lucena MI, et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009; 10: 956-970
60. Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PloS One 2011; 6: e27810
61. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34: 123-133
62. Kim SH, Ye YM, Palikhe NS, et al. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010; 10: 280-290
63. ONeil WM, MacArthur RD, Farrough MJ, et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002; 42: 613-619
64. Keen HI, Conaghan PG, Tett SE. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 2013; 12: 581-588
65. Pinto B, Dhir V, Krishnan S, Nada R. Leflunomide-induced DRESS syndrome with renal involvement and vasculitis. Clin Rheumatol 2013; 32: 689-693
66. Kalgutkar AS, Nguyen HT, Vaz AD, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003; 31: 1240-1250
67. Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64: 871-876
68. Sevilla-Mantilla C, Ortega L, Agundez JA, et al. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36: 82-84
69. Wiese MD, Schnabl M, ODoherty C, et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther 2012; 14: R163
70. Chan EC, New LS. In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metab Lett 2007; 1: 299-305
71. Huang JL, Wu SY, Xie XJ, et al. Inhibiting effects of leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. Eur J Pharmacol 2011; 670: 304-310
72. Luo SB, Li CB, Dai DP, et al. Characterization of a novel CYP2C9 mutation (1009CA) detected in a warfarin-sensitive patient. J Pharmacol Sci 2014; 125: 150-156
73. Ruiz JD, Martinez C, Anderson K, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PloS One 2012; 7: e44629